Q

Cutaneous Oncology ~



Healio > News > Dermatology > Cutaneous Oncology

## **American Society for Dermatologic Surgery**



By Kate Burba

Source/Disclosures

Source: Arzeno J, et al. Current practices for preventative interventions for nonmelanoma skin cancers among dermatologic surgeons. Presented at: American Society for Dermatologic Surgery annual meeting; Oct 9-11, 2020 (virtual meeting).

Disclosures: The authors report the study was supported by UCLA Dermatology Research and Education Fund and the NIH National Center for Advancing Translational Science UCLA CTSI grant number UL 1TR001881.

October 12, 2020 | 1 min read



## Dermatologic surgeons likely to propose pharmacologic nonmelanoma skin cancer prevention




Most dermatologic surgeons recommended pharmacologic interventions to <u>prevent nonmelanoma skin cancer</u>, according to a presentation at the American Society for Dermatologic Surgery annual meeting.

An eight-question survey was sent to dermatologic surgeons of the American College of Mohs Surgery to assess prescribing practices for <u>nonmelanoma skin cancer (NMSC)</u> prevention.

Of 85 respondents, 95.3% recommended intervention for NMSC prevention, with 84.2% recommending nicotinamide, 59.8% recommending actiretin and 39% recommending topical retinoids. Further analysis found 45% of respondents recommended preventive therapies after five or more NMSCs and more than 10% recommended preventive therapies among patients with actinic keratoses but no history of NMSC.


Physicians in practice for less than 5 years were 7.41 times more likely to recommend nicotinamide compared with those in practice for more than 15 years (P = .017). Physicians in academic settings were more likely to recommend twice-daily nicotinamide 500 mg compared with once-daily nicotinamide 500 mg for physicians in private practice (P = .01).

"Prescribing practices varied by years in practice — the observed differences cannot solely be attributed to differences in practice settings: There was no significant association between years in practice and practice setting," Julia Arzeno, MD, of the division of dermatology, University





Skin cancer biopsy rates among providers, top dermatology stories



of California, Los Angeles, and colleagues wrote. "Studies that directly compare the efficacy of preventative interventions for NMSCs and establish guidelines regarding the threshold for initiating such therapies are needed."

## **Related Content**



American Society for Dermatologic Surgery



American Academy of Dermatology Meeting The Future of Medicine 🗹

C. Everett Koop, Science, 2002

NSGC Panel Divided on Whether Newly Diagnosed Breast Cancer Patients Should Undergo Panel Testing

MORE FROM THIS MEETING

Turna Ray et al., GenomeWeb, 2019

Powered by TREND MD

Aurora Diagnostics Acquires Cleveland Skin Pathology Laboratory ☑

360Dx, 2017

Cynvenio, St. Luke's Partner on Breast Cancer Study 

360Dx, 2017

Follow Healio ♥ f in ふ


Tell us what you think about Healio.com >

**②** Help

## Sign Up for Email Get the latest news and education delivered to your inbox Email address Specialty All Specialties

My Saved
Log Out
Update Publication Mailing Address
Subscribe
My Account
Email Subscriptions and Alerts
Institutional and Library Subscriptions

**Account Information** 



Legal
Medical Disclaimer
Privacy Policy
Do Not Sell My Personal Information
Editorial Policy and Philosophy
Terms and Conditions
Permissions

©2020 Healio All Rights Reserved.

Help